scholarly journals Resucitación cardiopulmonar y cerebral en la embarazada. Al final del colapso materno

2014 ◽  
Vol 65 (3) ◽  
pp. 228 ◽  
Author(s):  
Mauricio Vasco-Ramírez

<p style="font: small/normal verdana; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><strong>Objetivo:</strong><span class="Apple-converted-space"> </span>proporcionar a los profesionales de la salud involucrados en el manejo de gestantes con complicaciones (obstetras, enfermeras, médicos generales y de emergencias, anestesiólogos, intensivistas, entre otros) los principios fundamentales de prevención y manejo de paro cardiorrespiratorio (PCR) en este grupo poblacional con el fin de mejorar los resultados del binomio madre-hijo.</p><p style="font: small/normal verdana; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><strong>Materiales y métodos:</strong><span class="Apple-converted-space"> </span>el documento se basa en una búsqueda de publicaciones en las bases de datos Medline, SciELO y Embase utilizando los términos "Cardiopulmonary Resuscitation, Pregnancy, Perimortem Cesarean, Maternal Cardiac Arrest, Cardiac arrest in pregnancy", y restringida a los siguientes tipos de publicación: "Meta Analysis, Systematic Reviews, Practice Guideline, Randomized Controlled Trial, Review, Case Report, Chapter, Editorial, Survey".</p><p style="font: small/normal verdana; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><strong>Resultados</strong>: se encontraron 78 títulos de los cuales se incluyeron 63; de estos, 22 corresponden a revisiones narrativas, 20 a reportes y series de caso, 8 a guías de práctica clínica, 5 a ensayos clínicos, 4 editoriales, 2 corresponden a revisiones sistemáticas o metaanálisis, 1 capítulo de libro y 1 encuesta o<span class="Apple-converted-space"> </span><em>survey</em>.</p><p style="font: small/normal verdana; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><strong>Conclusiones</strong>: el paro cardiaco en gestantes impone un reto al grupo interdisciplinario que lo enfrenta, por ser una entidad de baja frecuencia que se puede asociar a un alto grado de morbimortalidad materna y perinatal. Las principales acciones por realizar son: activación del código azul obstétrico con respuesta adecuada para realización de histerotomía de emergencia oportuna, compresiones torácicas de buena calidad, desviación manual uterina 15º a la izquierda cuando el útero grávido se palpe por encima del ombligo materno, manejo avanzado farmacológico y de vía aérea, y cuidado óptimo luego de la resucitación para la madre y el neonato.</p>

Addiction ◽  
2001 ◽  
Vol 96 (3) ◽  
pp. 485-494 ◽  
Author(s):  
Peter Hajek ◽  
Robert West ◽  
Anne Lee ◽  
Jonathan Foulds ◽  
Lesley Owen ◽  
...  

2018 ◽  
Vol 149 (4) ◽  
pp. 628-634 ◽  
Author(s):  
Rebecca Kofod Vinding ◽  
Jakob Stokholm ◽  
Astrid Sevelsted ◽  
Bo L Chawes ◽  
Klaus Bønnelykke ◽  
...  

ABSTRACT Background Randomized trials have reported that supplementation with n–3 long-chain polyunsaturated fatty acids (LCPUFAs) in pregnancy can prolong pregnancy and thereby increase birth weight. Objective We aimed to examine the relations of n–3 LCPUFA supplementation in pregnancy with duration of pregnancy, birth weight, and size for gestational age (GA). Methods This was a double-blind randomized controlled trial conducted in 736 pregnant women and their offspring, from the Copenhagen Prospective Studies on Asthma in Childhood2010cohort. They were recruited between weeks 22 and 26 in pregnancy and randomly assigned to either of 2.4 g n–3 LCPUFA or control (olive oil) daily until 1 wk after birth. Exclusion criteria were endocrine, cardiovascular, or nephrologic disorders and vitamin D supplementation intake >600 IU/d. In this study we analyzed secondary outcomes, and further excluded twin pregnancies and extrauterine death. The primary outcome for the trial was persistent wheeze or asthma. Results The random assignment ran between 2008 and 2010. Six hundred and ninety-nine mother-infant pairs were included in the analysis. n–3 LCPUFA compared with control was associated with a 2-d prolongation of pregnancy [median (IQR): 282 (275–288) d compared with 280 (273–286) d, P = 0.02], a 97-g higher birth weight (mean ± SD: 3601 ± 534 g compared with 3504 ± 528 g, P = 0.02), and an increased size for GA according to the Norwegian population-based growth curves-Skjærven (mean ± SD: 49.9 ± 28.3 percentiles compared with 44.5 ± 27.6 percentiles, P = 0.01). Conclusion Supplementing pregnant women with n–3 LCPUFAs during the third trimester is associated with prolonged gestation and increased size for GA, leading to a higher birth weight in this randomized controlled trial. This trial was registered at clinicaltrials.gov as NCT00798226.


Sign in / Sign up

Export Citation Format

Share Document